Autonomix Medical, Inc. is a development stage medical device development company focused on advancing innovative technologies for sensing and treating disorders relating to the nervous system. The company is headquartered in The Woodlands, Texas and currently employs 5 full-time employees. The company went IPO on 2024-01-29. Its technology platform includes a catheter-based microchip sensing array that has the ability to detect and differentiate peripheral neural signals with up to 1,000 times sensitivity. The company is developing a two-fold technology that can both detect malfunctioning neural signals and ablate nerves in one simple procedure for pain management. The company is developing its technology for pancreatic cancer and pancreatitis, conditions that can cause debilitating pain and need an effective solution. Its technology constitutes a platform with the potential to address dozens of indications, including in cardiology, renal denervation, and chronic pain management across a disease spectrum. Its Autonomix catheter is equipped with a microchip that converts analog signals from the body to a digital signal that can be sent directly to a computer screen.